Order Article Reprints

Sugimoto N, Noura S, Kato T, Yoshioka S, Hata T, Naito A, Tei M, Tamagawa H, Komori T, Ide Y, et al. The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses. Cancers. 2025; 17(1):91. https://doi.org/10.3390/cancers17010091

Sugimoto, Naotoshi, Shingo Noura, Takeshi Kato, Shinichi Yoshioka, Taishi Hata, Atsushi Naito, Mitsuyoshi Tei, Hiroshi Tamagawa, Takamichi Komori, Yoshihito Ide, and et al. 2025. "The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses" Cancers 17, no. 1: 91. https://doi.org/10.3390/cancers17010091

Sugimoto, N., Noura, S., Kato, T., Yoshioka, S., Hata, T., Naito, A., Tei, M., Tamagawa, H., Komori, T., Ide, Y., Fukuzaki, T., Danno, K., Sawada, G., Kagawa, Y., Shimokawa, T., Miyoshi, N., Ogino, T., Uemura, M., Yamamoto, H., ... Eguchi, H. (2025). The Efficacy of FOLFIRI Plus Ramucirumab in Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy with Oxaliplatin/Fluoropyrimidine—Including Biomarker Analyses. Cancers, 17(1), 91. https://doi.org/10.3390/cancers17010091